Lundbeck appoints former Roche exec as CBO

Keld Flintholm Jørgensen has been appointed chief business officer (CBO) heading corporate strategy and business development at Danish CNS specialist Lundbeck (LUND: CO), effective April 4, 2019. He will be part of executive management in his role as executive vice president, CBO.

The new position is established as part of the revised strategy which focuses on achievement of sustainable growth. This focus demands that Lundbeck supplements its internally generated pipeline with high quality assets from external sources. Lundbeck says it will access this external innovation through product license and/or acquisitions as well as through strategic partnerships.

Danish born Mr Jørgensen will join the company from a position as global head of strategic partnering for Swiss pharma giant Roche (ROG: SIX). Since 2011 Mr Jørgensen has worked in business development and partnering across multiple therapy areas, including CNS. During this period, he has been leading multiple global M&A projects, pharma and biotech partnering initiatives and strategic projects, building creative partnerships and deals to expand the Roche pipeline.